Dina Brauneis

482 total citations
24 papers, 298 citations indexed

About

Dina Brauneis is a scholar working on Molecular Biology, Genetics and Hematology. According to data from OpenAlex, Dina Brauneis has authored 24 papers receiving a total of 298 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 13 papers in Genetics and 11 papers in Hematology. Recurrent topics in Dina Brauneis's work include Amyloidosis: Diagnosis, Treatment, Outcomes (23 papers), Chronic Myeloid Leukemia Treatments (9 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (7 papers). Dina Brauneis is often cited by papers focused on Amyloidosis: Diagnosis, Treatment, Outcomes (23 papers), Chronic Myeloid Leukemia Treatments (9 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (7 papers). Dina Brauneis collaborates with scholars based in United States. Dina Brauneis's co-authors include Vaishali Sanchorawala, J. Mark Sloan, Shayna Sarosiek, Anthony C Shelton, Karen Quillen, Amanda Schulman, David C. Seldin, Andrea Havasi, Stephen Lo and Fangui Sun and has published in prestigious journals such as Blood, Leukemia and Bone Marrow Transplantation.

In The Last Decade

Dina Brauneis

21 papers receiving 296 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dina Brauneis United States	10	281	117	108	64	59	24	298
Andrew Staron United States	7	195 0.7×	50 0.4×	33 0.3×	40 0.6×	44 0.7×	24	208
JD Gillmore United Kingdom	7	283 1.0×	52 0.4×	27 0.3×	51 0.8×	90 1.5×	37	312
Ioanna Dialoupi Greece	9	140 0.5×	46 0.4×	106 1.0×	15 0.2×	61 1.0×	23	197
Sébastien Delbès France	3	165 0.6×	25 0.2×	24 0.2×	21 0.3×	43 0.7×	5	184
Ekaterina Balaian Germany	9	65 0.2×	80 0.7×	100 0.9×	10 0.2×	35 0.6×	16	208
Lia Liefaard United Kingdom	6	162 0.6×	44 0.4×	12 0.1×	18 0.3×	44 0.7×	11	231
Malte Aßhoff Austria	6	106 0.4×	192 1.6×	196 1.8×	10 0.2×	15 0.3×	11	291
Oscar Lahoud United States	8	99 0.4×	42 0.4×	89 0.8×	15 0.2×	70 1.2×	44	197
Onima Chowdhury United Kingdom	6	138 0.5×	145 1.2×	198 1.8×	97 1.5×	11 0.2×	10	326
Christian Reimann Germany	5	81 0.3×	40 0.3×	114 1.1×	11 0.2×	59 1.0×	7	220

Countries citing papers authored by Dina Brauneis

Since Specialization

Citations

This map shows the geographic impact of Dina Brauneis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dina Brauneis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dina Brauneis more than expected).

Fields of papers citing papers by Dina Brauneis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dina Brauneis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dina Brauneis. The network helps show where Dina Brauneis may publish in the future.

Co-authorship network of co-authors of Dina Brauneis

This figure shows the co-authorship network connecting the top 25 collaborators of Dina Brauneis. A scholar is included among the top collaborators of Dina Brauneis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dina Brauneis. Dina Brauneis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Brauneis, Dina, et al.. (2022). Modified High-Dose versus High-Dose Melphalan Conditioning in Older Patients Undergoing Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis. Transplantation and Cellular Therapy. 28(11). 761.e1–761.e7. 2 indexed citations

Sarosiek, Shayna, et al.. (2020). Comparing measures of hematologic response after high-dose melphalan and stem cell transplantation in AL amyloidosis. Blood Cancer Journal. 10(8). 88–88. 9 indexed citations

Szalat, Raphaël, Shayna Sarosiek, Andrea Havasi, et al.. (2020). Organ responses after highdose melphalan and stemcell transplantation in AL amyloidosis. Leukemia. 35(3). 916–919. 18 indexed citations

Patel, Monica, Dina Brauneis, Vaishali Sanchorawala, et al.. (2020). Left Atrial Mechanics Associates With Paroxysmal Atrial Fibrillation in Light-Chain Amyloidosis Following Stem Cell Transplantation. JACC CardioOncology. 2(5). 721–731. 12 indexed citations

Brauneis, Dina, Anthony C Shelton, Karen Quillen, et al.. (2019). Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed by Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis: Long-Term Follow-Up Analysis. Biology of Blood and Marrow Transplantation. 25(5). e169–e173. 15 indexed citations

Sarosiek, Shayna, J. Mark Sloan, Karen Quillen, et al.. (2019). Safety and Efficacy of Propylene Glycol-Free Melphalan (Evomela) in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Preliminary Results of a Phase II Study. Blood. 134(Supplement_1). 4578–4578. 1 indexed citations

Sanchorawala, Vaishali, Dina Brauneis, J. Mark Sloan, et al.. (2019). High-dose melphalan and autologous peripheral blood stem cell transplantation in patients with AL amyloidosis and cardiac defibrillators. Bone Marrow Transplantation. 54(8). 1304–1309. 6 indexed citations

Nguyen, Vina P., Heather Landau, Karen Quillen, et al.. (2018). Modified High-Dose Melphalan and Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis. Biology of Blood and Marrow Transplantation. 24(9). 1823–1827. 15 indexed citations

Brauneis, Dina, Anthony C Shelton, Vaishali Sanchorawala, et al.. (2018). Evaluation of a new continuous mononuclear cell collection procedure in a single transplant center cohort enriched for AL amyloidosis patients. Transfusion and Apheresis Science. 57(3). 411–415. 1 indexed citations

10.

Sarosiek, Shayna, Karen Quillen, J. Mark Sloan, Dina Brauneis, & Vaishali Sanchorawala. (2018). Heparin-induced thrombocytopenia and thrombosis during high dose melphalan and autologous stem cell transplantation. Blood. 132(7). 755–757. 3 indexed citations

11.

Sanchorawala, Vaishali, Shayna Sarosiek, J. Mark Sloan, et al.. (2018). Safety, Tolerability and Response Rates of Daratumumab in Patients with Relapsed Light Chain (AL) Amyloidosis: Results of a Phase II Study. Blood. 132(Supplement 1). 2005–2005. 10 indexed citations

12.

Sanchorawala, Vaishali, Shayna Sarosiek, J. Mark Sloan, et al.. (2017). Safety and Tolerability of Daratumumab in Patients with Relapsed Light Chain (AL) Amyloidosis: Preliminary Results of a Phase II Study. Blood. 130. 507–507. 13 indexed citations

13.

Nguyen, Vina P., Dina Brauneis, J. Mark Sloan, et al.. (2017). Brachial Plexopathy Following High-Dose Melphalan and Autologous Peripheral Blood Stem Cell Transplantation for AL Amyloidosis. Blood. 130. 5509–5509.

14.

Batalini, Felipe, Laura Econimo, Karen Quillen, et al.. (2017). High-Dose Melphalan and Stem Cell Transplantation in Patients on Dialysis Due to Immunoglobulin Light-Chain Amyloidosis and Monoclonal Immunoglobulin Deposition Disease. Biology of Blood and Marrow Transplantation. 24(1). 127–132. 25 indexed citations

15.

Meehan, Robert, David C. Seldin, J. Mark Sloan, et al.. (2016). Effect of severe hypoalbuminemia on toxicity of high-dose melphalan and autologous stem cell transplantation in patients with AL amyloidosis. Bone Marrow Transplantation. 51(10). 1318–1322. 4 indexed citations

16.

Sanchorawala, Vaishali, Dina Brauneis, Anthony C Shelton, et al.. (2015). Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial. Biology of Blood and Marrow Transplantation. 21(8). 1445–1451. 49 indexed citations

17.

Brauneis, Dina, Frederick L. Ruberg, Anthony C Shelton, et al.. (2015). The Incidence of Atrial Fibrillation Among Patients with AL Amyloidosis Undergoing High Dose Melphalan and Stem Cell Transplantation (HDM/SCT): Experience at a Single Institution. Blood. 126(23). 5490–5490. 1 indexed citations

18.

Sanchorawala, Vaishali, Gheorghe Doros, Karen Quillen, et al.. (2014). Long-Term Outcome of Patients with AL Amyloidosis Treated with High-Dose Melphalan and Stem Cell Transplantation: 19 Year Experience at a Single Center. Biology of Blood and Marrow Transplantation. 20(2). S47–S48. 1 indexed citations

19.

Sanchorawala, Vaishali, Gheorghe Doros, Karen Quillen, et al.. (2013). Long-Term Outcome Of Patients With AL Amyloidosis Treated With High-Dose Melphalan and Stem Cell Transplantation: 19 Year Experience At a Single Center. Blood. 122(21). 3328–3328. 1 indexed citations

20.

Sanchorawala, Vaishali, Anthony C Shelton, Dina Brauneis, et al.. (2012). Treatment of AL Amyloidosis with Two Cycles of Induction Therapy with Bortezomib and Dexamethasone Followed by Bortezomib-High Dose Melphalan Conditioning and Autologous Stem Cell Transplantation. Blood. 120(21). 2019–2019. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact